full fda approval could occur within a few days. this would be the third coronavirus vaccine approved by the fda. the johnson & johnson vaccine can be given as a single dose. with the biden administration now leading the federal response to the coronavirus pandemic, follow the latest at cspan.org/coronavirus printed search cspan's coverage of news conferences as well as remarks from members of congress. use the interactive gallery to follow the cases in the u.s. and worldwide. thirty cspan.org/coronavirus rated and trent. tuesday fbi director christopher wright testifies before the senate do just a rere committee regarding the fbi security and planning in advance of entering the attack on the capitol on january 6th. watch our live coverage at 10:0n three. also cspan.org or listen live on the c-span radio app. while in texas yesterday president biden's coronavirus vaccinations site as the stadium

most assume it means fda approval. we may never have fda approval onany of these vaccines , especially related to placebo-controlled roots on the ongoing phase 3 clinical trials. these vaccines need to continually be framed as investigational and we are learning as we go in the real world. with all the risks that entails. it seems eua has become the new standard with new variants popping up there will be an endless market for potential leadership. work speed testing, then deploy and hopefor the best seems to be the new accessible strategy . is the public being given true informed consent and made aware of these vaccines are still investigational and may not transmission , may not stop there life, have not been tested on all people like those with immune deficiencies and pregnancy and now we are seeing politicians and influencers joining in on the mass vaccination efforts while telling the public the shots to take. how can the public be assured harmed adverse events are being taken seriously western mark the adverse eve

the committee will advise the fda in the assessment of the data, continue fda's commitment to expedited review process that is transparent, scientifically found and data-driven. and this slide is presented for this describing the legal basis for issuing an eua and represented in the two previous advisory committees last december. as a reminder the health and human services secretary issued the declaration on march-- 2020. [inaudible] biontech and moderna covid 19 vaccines are available for covid-19. quantity available for mass vaccination is currently limited. the fda expectations for covid-19 vaccine eua's were discussed previously at the october 22nd and december 10th and 17th, 2020 advisory committee meetings and are described in the fda guidance, emergency use authorization for vaccine to prevent covid-19 published in october of 2020 and updated on february 22nd, 20211. there are three areas under which our expectations are covered. data-- the first data to demonstrate manufacturing quality and consistency, clear and compelling safety and data to support favorable benefit risk of th

welcome to the 164 meeting a vaccine and related biological products meeting i am project manager with fda and i will be the facilitator this is a live virtual public meeting broadcast in its entirety through c-span, facebook live, youtube, twitter and various other methods. it will be posted on the webpage along with all relevant meeting materials. i will reminder speakers and presenters and committee members and sponsors when they are close to their allotted timeed and assisting when needed. just a reminder, once called upon please activate your webcam and activate your mute we are aware of the adverse weather conditionswa some of you having to take precautions and we will take a scheduled break i like to introduce the acting chair who will now provide opening remarks. please activate your webcam and taken away. >> goodin morning. i would like to open this meeting, 164th meeting of the vaccine related biological products advisory committee. and to specifically tell us the reason for the meeting to provide and discuss emergency use authorization of the johnson & johnson biotech covid-19 v

today we are talkingng about fda and cdc's advisory committees.r writer with staff use here to talk about these two advisory committees, let's begin with the fda. what is there advisory committee? >> the advisory committee helps them on issues related to the approval of vaccinations, vaccines vaccines and related biological products advisory committee, mostly people -- [inaudible] >> they are set to meet this week. what are they expected to talk about? >> you remember when the fdada s under political pressure to fast-track the vaccines and then commissioner stephen was trying verywa hard to safeguard the process to approve vaccines, make sure they were based on science, not political expediency, made the commitment that it would reach every time there's a new covered vaccine to be considered for emergency use authorization. since then, he's kept that promise every time, he's no longer in office but the fda has kept that promise everyy time a new covered vaccine is ready by fda to continue to consider whether or not tode issue emergency use authori

most assume it is fda approval we may never have fda approval on any vaccine especially but the ongoing phase three clinical trials. and we are learning as we go in the real world. it seems eua is the new standard with variance popping up there will be an endless market for endless booster shots. and at the public giving true consent that they investigational and may not stop transition has not impacted on with those immune deficiency now we see celebrity politician from answers joining in on the mass vaccination ever telling the public the shots are safe. how do we know these adverse events are taken seriously? so we have seen in the shortn st term are being dismissed and accepted as the vaccine is working as priming the immune system. they take the proper reporting measures to the fda and cdc to this day none of them have been contacted or followed up by the companies. weeker earlier this first months of shots of no safety issues with pfizer or the teethree vaccine. we haven't seen immune system fertility or other health issues ultimately the real world clinical trial it is one big hu

chattergee, is this for fda,? >> yes. >> okay. >> my question is i had trouble with the breathing document, trying to distinguish between where the cutoff was for severe disease. because the way the data were presented, it was mod rate to severe and then severe-critical. and so i couldn't figure out is this a continuum? where's the cutoff? >> thank you for that question. yes, there is a cutoff, and in one of the slides in my presentation there is a separate analysis for just severe critical disease. and as i mentioned in the presentation, for it to meet that severe critical disease endpoint, it has to undergo adjudication by the blind add jude case committee and what their decision is when they review the data, that is the final determination of whether that case is severe or not. so it is a distinct -- [inaudible] >> so when talking about moderate to severe disease, that is separate from the severe critical, right? and that's dependent on the adjudication committee, is that correct? >> the moderate to severe endp

most assume it means fda approval. we may never have fda approval onany of these vaccines , especially related to placebo-controlled roots on the ongoing phase 3 clinical trials. these vaccines need to continually be framed as investigational and we are learning as we go in the real world. with all the risks that entails. it seems eua has become the new standard with new variants popping up there will be an endless market for potential leadership. work speed testing, then deploy and hopefor the best seems to be the new accessible strategy . is the public being given true informed consent and made aware of these vaccines are still investigational and may not transmission , may not stop there life, have not been tested on all people like those with immune deficiencies and pregnancy and now we are seeing politicians and influencers joining in on the mass vaccination efforts while telling the public the shots to take. how can the public be assured harmed adverse events are being taken seriously western mark the adverse eve

these are adverse events of interesthe fda focuses on. i wanted to mention these studies and other vaccines but they haven't been associated with the covid vaccine and preauthorization studies. some of the things you seen in hiprevious studies, a syndrome cerebral palsy and etc. i want to talk about the rarity of these events, one in 10000, one in 100,000 or less so they are rare. large databases in many cases, in order to get the significant power in order too analyze usually with millions of patients. the cms data, just to remind people, the previous presentation to this committee, on the date of coverage, illegal 55 million elderly beneficiaries over 65 years of age in the u.s., here is the accounts we are getting, in the cms medicare data, we got 4.8 million total doses and to orient you on the graphic, the far left as far as total number, the middle is the first dose, the right bar that is second dose and as you can see for pfizer, two-point 8 million doses and 2 million doses for the moderna vaccine. for this analysis, this is liste

guest: that has been presented at the fda advisory committee. i agree with the caller that it's important that people understand so they can make decisions. what i would say is things like pain at the site of injection occurs in the majority of people. in a smaller number, things like muscle aches, fevers, almost flulike. it doesn't occur in most patients, it occurs in a lot. my health care workers, myself included, thousands in our system, what i saw in my immediate colleagues it was about one out of 10 had to miss the day of work because they felt so miserable. in the overwhelming majority, within a couple of days they are back to normal. so far, those haven't been detected in patients receiving the vaccine. there is a lot of safety monitoring going on. i would say these are side effects people can live with as long as they are aware of it. you can have fever and chills. my own personal experience was pretty benign. i had a sore arm. everyone is going to have different experiences. be prepared that you might feel sick for a couple of days. hos

an fda panel endorsed it, and any day now the fda will give its final stamp of approval. if approved, it will be the first single-dose covid vaccine in the united states. another difference, it can be kept in a normal fridge, that temperature, so it's easier to appears effective against the new variants of the virus. final approval could come as early as this weekend. so what does that mean for us here in california? governor newsom says the j&j doses could arrive here by next week. he made the announcement today during a visit to fresno county. the governor says the first batch of doses for our state

in fact, no covid vaccine is fda approved at this point. here is the good news. this shot only requires one dose. it's much easier to store as it can sit in most standard refrigerators for at least three months. the caveat addressed today is experts stressed in order for this vaccine to be reliable and continue to improve efficacy, consistent data reporting needs to be prioritized. citing of the 66 million doses administered across the country, we still don't have any data on how many people have been reinfected after receiving the vaccine. until that happens, experts concluded this vaccine has the ability to prevent severe disease and further hospitalization, getting us one step closer to immunity. >> typically if you have immunity, two things happen. you either have a lot less of the virus so it's not really replicating and causing your body to rev up the way that it would if you didn't have any immunity in place, and it typically keeps it from going to other places. >> johnson & johnson is on track to deliver 100 million doses by the end of june. this, of cour

what is the fda releasing with this? >> yeah. this is the fda's analysis of this data. let's put the numbers up and i'll talk you through this a little bit. i think this is important. when we look at the numbers in terms of how protective this vaccine is against moderate and severe disease, i can tell you these numbers are a little different from what we first heard from johnson & johnson and they're a little better. the south african variant circulating predominantly in south africa, previously it was thought to be 57% protective against moderate and severe disease. a little better now. kate, you can see there's the difference, the u.s. 72%, that's the coronavirus strain circulating here. in latin america, that's more likely the strain circulating in brazil and then the variant in south africa. there is a difference, and that's something to make note of in terms of how much of a difference these strains, how protective the vaccine will be. it was the bottom number to your question, 85% across the board globally where they said it's 85% protective against severe and cri

fda's advisory committee will meet later this week. assuming necessary regulatory approvals, we are ready to begin shipping immediately and deliver in a single doses by end of march, april vaccination of more than 20 million americans. furthermore, we will meet our target to deliver 100 million single-dose vaccines to the u.s. during the first half of 2021. we've been working to expand manufacturing capacity in contract with third-party manufacturers for additional production. we assess nearly 100 different production sites and we've selected the site able to support and accelerate timeline. we are working around the clock for manufacturing capabilities to supply the u.s. with vaccine. our plans call for production in the u.s., europe, africa and asia. our vaccine can be distributed using the existing supply chain and routine refrigeration we used to transport other medicines today. the vaccine is based on johnson & johnson technology, we have significant political experience with vaccines based on this technology including vaccines ad

now weeks later and this new fda report tonight just as encouraging. let's just reiterate here, 86% effective against severe illness in theist. 100% effective at preventing hospitalizations and death. a single shot. doesn't have to be stored at those deep freeze temperatures. so, i guess the question tonight is, is this a game changer? >> david, thank you for having me back. it's wonderful news. it is just one more piece of really good news on the vaccine front. i think it's going to make an enormous difference. it's going to be so much easier to store and get out to people. and look, what we care about most is those hospitalizations and deaths. and this vaccine seems terrific at preventing that and that's what matters. >> and obviously we just don't know how this could effect the ultimate timeline for vaccinates americans and no one wants to overpromise here. but let's look at what we do know tonight. pfizer and moderna have promised to meet that deadline of 300 million doses each by the end of july. that's enough for all americans. now johnson & john

the fda saying the vaccine had the expected side effects like fever and fatigue. and the company is looking into preliminary reports of two severe allergic reactions as seen in other vaccines. but top health experts calling it safe. >> we now have three highly effective vaccines. importantly, each of them are very effective against severe disease, and virtually all of them say that you look at the data, and it's clear that you get essentially no hospitalizations or deaths in any of them. this is very good news. >> reporter: and unlike the others, j&j was tested in communities with concerning variants and still performed well. the johnson & johnson vaccine is also easier to store at normal refrigerated temperatures. >> we need vaccines that are effective and well tolerated and importantly, ones that are simple to deploy. >> reporter: teams inside this lab near baltimore have been working around the clock on the vaccine. >> since september, that's when the manufacturing started. our engineering runs and, we have been in constant production since. >> reporter: from p

the data is not with the fda. they are examining it. they have scheduled the advisory committee, the vaccine related biological product advisory committee, which will meet in three weeks. let me review your we are and where we hope to go. as you know, data on efficacy of this ensemble trial, which involved three countries, the united states, brazil and the republic of south africa -- has been passed from the different countries. you had 72% efficacy for mild to moderate disease in the u.s. in the republic of south africa, which as you know is of concern to us because of the mutant, and the lineage that is now dominant in the republic of south africa, namely the b-1 351, in that the protection against moderate disease with 57%. -- was 57%. but the good news, when you look across all countries, protection against truly serious disease was about 88.8%. also of interest was that, in the south african study as well as all the others, there were essentially no hospitalizations or death. so the sobering news is that we are dealing with variant

we'll see what fda doesn't care. so the there is a lot of work now being done on the 2 vaccines that are currently authorized for and as you suggest. they are looking at different ways in which to deliver them. maybe different ways in which to spread out the doses or maybe a all of that is actually being worked now so there are likely to be changes. we got these out as quickly as we could because of the efficacy and safety profiles and we needed to get them out now for the pandemic but things could change rapidly just like the pandemic so johnson johnson's vaccine is somewhere between 7285% effective in preventing severe disease. but. >>pfizer's and moderna's are anywhere from like 94 to 95%. what's the difference there and doesn't matter. >>yeah actually severe disease this new one is almost a 100% that can see against any diseases lower. so we did see some infection rates. but really our goal actually is to keep people out of the hospital and keep people from passing away from this and so the goal really was not al

yesterday, the fda committee approved the johnson & johnson vaccine for emergency use authorization. tell us what that means. what happens now? guest: it means the fda weighed the evidence for large clinical trial of over 40,000 people and determined it was safe and effective in reducing covid-19 illness. that means if the fda goes along with the advisory committee deliberations, that vaccine will become available relatively quickly, as early as next week. the company has going to be ramping up significantly and increase the vaccine supply. it's good news. host: what are the differences between the johnson & johnson vaccine and the ones that we have heard so much about, the ones being used right now? guest: one big difference is it is one dose.

fda authorization of the johnson & johnson vaccine could come as early as this weekend.if that happens, the vaccine could be headed to states next week. johnson & johnson says it expects to provide 20 million doses by the end of march. according to documents obtained by cbs2 news, the cdc expects the vaccine will be recommended for use on sund. ve in silver s maryland, madeleine rivera, back to you. >>> for the latest on the coronavirus vaccine, eligibility, and where to get it, go to kpix.com/vaccine. >>> as soon as this evening how's lawmakers are expected to pass president biden's nearly 2 trillion-dollar covid relief package. it covers a lot of bases and includes $1400 stimulus checks for individuals earning less than $75,000 a year. and boosts federal unappointed payments to $400 a week. it also includes funding for school reopening's, assistance for rent and food, money for vaccine distribution, and aid for state and local governments. the house version includes a $15 an hour minimum wage provision. but in the senate the says it cannot survive the process. democrat

expertos de la fda dieron luz verde a la vacuna de johnson and johnson dieron la tercera opción en laus impuso la muerte grupo de asesores indefensos de la fda le dio el visto bueno este viernes a la vacuna de johnson and johnson praxis para comenzar a administrar tan pronto como la semana próxima a pesar de esto la fda no está obligada a seguirla le comercio del panel pero generalmente lo haces. los de la zona johnson a johnson es como una reacción del contéstame como el riesgo de síntomas severos 14 días después de la vacunación dijo una de los personas viendo de contra la fda este tercer vacuna requiere una sola dosis y los ensayos mostró una eficacia del 70 y los por ciento en los estados unidos y un 86% en la prevención de las manifestaciones más graves del comente tanto la fda dijo que puede ser almacenada a congelación estándar por dos semanas, inicialmente se refería quela vacuna fuera puesta a mucho frío. nuevo estudio demostró que las enfermedades de las esencias pueden causar más de mal aliento y la descomposición del dientes de acuerdo a la investigación publicada en una r

one, such as remdesivir, has gained fda approval. its effect is clear but modest. when regard to getting early intervention, monoclonal antibodies, both from lilly and from regeneron, have received emergency use authorization. here again, the earlier one uses these, the better. these are as efficient and more efficient in those individuals who don't necessarily have a good antibody response. the same can be said of convalescent plasma, which has also earned an emergency use authorization -- again, because of the variability in the titer of antibody in various plasma -- excuse me, plasma aliquots. the issue here is getting this as early as possible. there have been a number of trials of a variety of antivirals or other agents that are off the shelf that have not been targeted. i'll get to targeted intervention in just a moment. and then hyperimmune globulin is also in clinical trial. and we await the results of all of these. with regard to therapeutics for advanced disease, as i mentioned, that is generally aimed at blocking an aberrant inflammatory or immunological

tambiÉn la fda aprobÓ el almacenamiento de la vacuna de pfizer—biontech a temperatura estÁndar en losesto le pone fin a los problemas a la hora de guardarla, evita la compra de equipos para mantener la ultra frÍa, y facilita el transporte para su distribuciÓn inmediata. antes tenÍa que guardarse en congeladores aproximadamente a 112 grados fahrenheit. nos contemos con el doctor jefe de... bienvenido a la "ediciÓn digital", la fda dice que se puede guardar la vacuna de johnson&johnson hasta dos semanas. ¿cÓmo cambia eso las cosas? >> buenos dÍas. gracias por la invitaciÓn. como decÍas en tu introducciÓn, la fda aprobado el almacenamiento, la distribuciÓn de nuestra vacuna en freezer normales o comerciales. lo cual hace mucho mÁs flexible el proceso de envÍo y distribuciÓn de nuestra vacuna. como sabes, la vacuna requiere para su conservaciÓn en largo tiempo, hasta seis meses, un freezer de ultra baja temperatura, de —80 grados. pero esta posibilidad de almacenarla hasta —20, nos permite hasta dos semanas de flexibilidad para transportar la vacuna desde un centro otro, y almacenarla dur

usually the fda follows their recommendations and we'd see the fda authorize this vaccine. but it the still not over. on sunday, the cdc advisory committee meets to give vaccine recommendations. that is the who, when, how is this all going to work with the vaccine. after that, another signoff from the cdc director and then that is when you're going to start seeing this distribution roll out, kate. >> and talk to me about the last bit, next week. assuming the vaccines are authorized for emergency use, how long before it is reasonable that shots are out and available? >> reporter: well, a lot of this will depend on the cdc advisory committee. right now we've been told by johnson & johnson, they've willing to put out the doses, but we're still awaiting what the advisory says, are they recommending certain communities or younger or older people and figure out how they're going to distribute to the groups following the guidelines of the cdc. but this is all still expected to happen next week. i've talked to multiple state officials are extremely excite and they're hearing they'r

the fda analysis shows this vaccine has a lower efficacy than the others.67% effective against moderate to severe covid-19 at least two weeks after the shot. >> what is the goal of the vaccine? to prevent you from getting really sick, needing hospitalizations and death. and this vaccine seems to work pretty well in that regard. >> reporter: i'm mandy gaither. >>> new details. we just learned san francisco could enter the state's red reopening tier by next wednesday. mayor london breed tweeted the news just in the past 30 minutes, saying the city is seeing continued improvement in the required covid-19 health indicators. under the red tier more businesses could reopen but mayor breed reminds people this is not a sign that we can let our guard down. san mateo and marin counties officially jumped from the purple tier into the red at midnight. that means indoor dining, gyms and movie theaters can reopen for the first time in months with limit -- >> and people lined up -- go ahead, ama. i'm sorry. you're back. >> that's okay. sorry about that. cinemark says this

could be packaged and moved once fda gives its approval. it will be the third vaccine here in the united states and first vaccine to require one dose instead of two. msnbc kathy park and msnbc medical contributor dr. patel. appreciate it. welcome, both. as we're awaiting this covid vaccine approval from johnson and johnson, take us through where we are currently and what we can expect once it goes through the formal approval process and is ready to go. >> yep. hey, yasmin. good afternoon to you. that's right. right now we are essentially in stand by mode. and you just said it, we are moments away from the approval from the fda for emergency use authorization when it comes to the j & j vaccine. once that clears and is likely clear some point this weekend, it will go to an advisory committee with the cdc who will then decide which groups will get the vaccine. so this has been the protocol that the other vaccines pfizer, moderna have followed as well. and once all of those hurdles have been cleared, the pharmaceutical giant will essentially be

the fda says it has expected side effects including fever and fatigue. company is looking into preliminary reports of two severe allergic reactions as seen in other vaccines. top health officials say it's safe. the johnson & johnson vaccine is also easier to transport and can be refrigerated at normal temperatures. when given emergency authorization more than 4 million doses could be deployed. it's possible by the end of july mod modorna and pfizer will deliver 600 million doses which means a surplus in the u.s. health officials are taking nuthing for granted. >> we may be done with the virus, but clearly the virus is not done with us. we cannot get comfortable or give into a false sense of security that the worst of the pandemic is behind us. >> reporter: christine sloane, abc news, new york. >>> a new clinic is opening up in san jose part of the outreach to disproportionately affected communities. the east valley clinic is located on mckee road in east san jose. chris nguyen was there for opening day. >> reporter: a new covid-19 vaccination site is now

i want to read a statement coming from the fda.thorization allows people 18 and older to be able to use this vaccine, for it to be distributed in the use for use in individuals 18 and older. the acting fda commissioner says in a quote, the authorization of this vaccine expands the availability of vaccines, the best medical prevention method for covid-19 to help us in the fight against this pandemic which has claimed over 500,000 lives in the united states. so here's what's going to happen next. we expect tomorrow at some point for a cdc advisory group to meet. they have to meet before we can actually see these vaccines go out and start making their way towards the appropriate health care area so that they can get in people's arms. so that cdc advisory group, they're the group that meets and they put out recommendations in terms of how this vaccine should be used and who it should be used for. remember, they put out all those recommendations in the past saying, this should probably first go to individuals 65 and older. then people w

>>and as the fda continues to evaluate the country's 3rd coronavirus vaccine. the white house is opening more community vaccination centers, the team just announced today 4 in florida and one in pennsylvania that will be able to eventually that vaccinate thousands of people every day once up and running live in washington. i'm jessi tenure. >>thank you jesse pfizer is seeking approval now from the fda to store its vaccine. at higher temperatures potentially making distribution much easier right now pfizer's vaccine has to be stored in those ultra cold freezers between -76 in -112 degrees fahrenheit. the company's now submitted new data to the fda showing the vaccine can remain stable between -13 -5 degrees. if the fda grants, the request it would make logistics of delivering the pfizer vaccine much easier potentially speed up distribution and pfizer is also started a large scale clinical trial to the safety and efficacy of the vaccines on pregnant women. the company hopes to enroll for 1000 pregnant women across the globe in this trial. >>participants in the u.

the fda has cleared the joh

i'll have more to say after the day of the fda review. we've been laider focused on the greatest operational challenges the country has undertaken administering shots in the arms of hundreds of millions of americans, increasing the nun of vaccinators. you may have the vaccine but not enough people to put the vaccine in someone's arm like you just saw. we brought back retired doctors and nurses, already deployed more than 1,500 medical personnel you see from natural disasters from the federal emergency management agency, fema and we commissioned our commission corps from the department of health and human services and the defense department, including the national guard, supplying vaccinators and lining up thousands more to do the vaccinations and also setting up more places for people to get vaccinated. oz of today we provided $3.8 billion to states, territories and tribes to create new vaccination centers and ramp up the existing one already, working with governors across the country in red and blue states to bolster their efforts to sta

but the fda says it has expected side effects including fever and fatigue.he company is also looking into preliminary reports of two severe allergic reactions as seen in other vaccines. top health officials say it's safe. the johnson & johnson vaccine is also easier to transport and can be refrigerated at normal temperatures. when given emergency authorization, up to 4 million doses could be deployed. it's possible by the end of july, modern and pfizer will deliver the last of their 600 million doses which would mean a surplus of vaccines in the u.s. health officials are taking nothing for granted. >> we may be done with the virus but clearly the virus is not done with us. we cannot get comfortable or give in to a false sense of s security that the worst of the pandemic is behind us. chris steen sloane, abc news, new york. >>> a new clinic in san jose part of the continuing outreach to disproportionately affected communities. the east valley clinic is located on mckee road in east san jose. ris part of an effort to make doses available to those who need it m

final authorization from the fda is expected within the next 24 hours. and on sunday a cdc panel will meet to discuss prioritizing the deployment of this new vaccine. that means up to 4 million doses could be shipped starting on monday with a potential of shots in arms by tuesday. so things begin to move very quickly from here. >>> now, california is expecting to get the johnson & johnson vaccine as early as next week. "abc 7 news" reporter luz pena is part of our abc 7 vaccine team. she spoke with several experts about vaccine distribution for the state, including one of the local doctors who was part of today's fda advisory committee. >> reporter: in the war against covid-19, there is hope today. the johnson & johnson vaccine is a step closer to getting authorized. were there any concerns as you were reviewing the data? >> we really didn't have any concerns. there's not a big safety signal here. >> reporter: dr. ganltz is part of the fda panel that gave the vaccine the green light today. data shows the one-dose johnson & johnson vaccine is 85% effectiv

this briefing comes as we just got that huge update from the fda.le shot vaccine for emergency use. it could be approved this week. this will be the first time that we hear from our nation's pandemic leadership since johnson & johnson news broke. we will take you to that as soon as it starts. >>> jeff bennett is my partner here for this hour. he is keeping an eye on the briefing. also a lot of movement in our nation's capitol. >> that's right. great to see you. what's happening today has big implications for all of us. in a matter of hours, president biden and the vice president will meet with a bipartisan group of lawmakers on an effort to support products made here in america. he will sign an executive order to shore up our supply chains. plus, over on capitol hill, we are watching several critical hearing. cabinet picks are being vetted. many are still not confirmed. the postmaster general is being grilled right now over delivery delays at the u.s. postal service. we will find out whether a 15

even before the johnson and johnson covid-19 vaccine received its final fda approval. the governor said more than a million doses will be coming to california over the next 3 weeks 380,300 next week week after and the week after so it's consistent based on that 3 week when the right now california is administering 1.4 million doses of vaccine. each week. but with johnson and johnson coming on board plus moderna and pfizer allocations increasing newsom says the state hopes to administer 4 million doses a week eventually and the governor says the next priority group those 16 to 64 with underlying conditions may be eligible before the target date of march 15th, the reason we're feeling we can do that is we have a preview into increased allocations particularly j j. >>they give us confidence and the ability to be more flexible in terms of moving that date forward to accommodate those unique needs of unique individuals that are struggling with those co-morbidities the governor also announced beginning march first the way vaccine is distributed in the state will change or mo

the fda meets to review the safety of johnson's one-shot vaccine. the timeline for when shots could actually be in arms. >> at about 8:00 this morning, johnson and johnson will begin its presentation to answer questions about its one-shot vaccine. the independent advisors will debate if the evidence is strong enough to recommend the shot. with that advice the fda is expected to grant the emergence use authorization as soon as tonight or tomorrow. >> now that it is only one shot we're going to be able to vaccinate more people by the end of june. >> in addition to being a singleshot dose. another advantage is the johnson and johnson vaccine only requires refrigeration. if authorized, 3-4 million doses would be shipped initially. johnson and johnson plans to have 100 million doses by the end of june. it would likely have a surplus in the united states. pfizer and moderna are already on track to deliver enough for 300 million people by july. >>> new this morning. more and more americans are planning to be vaccinated. at least 55% of americans have gotte

the fda is talking about tweaking vaccines. but right now they are effective. >> some think the uk variant could become the dominant strain in california. tom barton has a good question, one i wanted to ask. what's your opinion in mixing the vaccines as they are trying in the uk? >> tom, there are early studies now happening about people -- people -- i shouldn't say people about vaccine manufacturers mixing doses. there is a study right now with pfizer and astrazenica. another study with pfizer -- stra zinc and sputnik v, the the one from russia. this is a concept called hitterologious prime boosting vaccination. the in her is when you give your immune system the same target with different strategies it may give you a more robust immune response. as of right now there is no recommendation for people to mix shots. we doesn't have the data to show that this is actually going to be more effective than what we are currently doing with giving the people the same shot with pfizer owner moderna or the johnson & johnson. but this may c

final authorization from the fda is expected within the next 24 hours. and on sunday a cdc panel will meet to discuss prioritizing the deployment of this new vaccine. that means up to 4 million doses could be shipped starting on monday with a potential of shots in arms by tuesday. so things begin to move very quickly from here. >>> now, california is expecting to get the johnson & johnson vaccine as early as next week. "abc 7 news" reporter luz pena is part of our abc 7 vaccine team. she spoke with several experts about vaccine distribution for the state, including one of the local doctors who was part of today's fda advisory committee. >> reporter: in the war against covid-19, there is hope today. the johnson & johnson vaccine is a step closer to getting authorized. were there any concerns as you were reviewing the data? >> we really didn't have any concerns. there's not a big safety signal here. >> reporter: dr. ganltz is part of the fda panel that gave the vaccine the green light today. data shows the one-dose johnson & johnson vaccine is 85% effectiv

the fda has kept that promise.ry time a new covid vaccine is ready to be studied by the fda, to consider whether or not to issue an emergency use authorization, they have convened a meeting. that is what has -- is happening this week to look at the johnson & johnson vaccine. host: we will have coverage of that meeting here on c-span. who sits on this advisory committee, and how do you get a post? guest: it is a variety of experts. there are 15 voting members and a few -- voting members, but the fda also has the right to add people to the committee on a case-by-case basis if they feel there is a need for more expertise in a particular area than is currently sitting on the committee. people on the committee are often infectious disease experts, internal medicine experts, biostatisticians, people who have experience with the rollout of vaccines, people who have a fair amount of deep knowledge about vaccinations and how they work and how they are used. in terms of how you get on the committee, one can apply. you can ap

an fda official writing in part, after a thorough analysis of the data, the fda scientists and physicians have determined the vaccine meets the fda's expectations for safety and effectiveness. president biden celebrating the news and praising the progress, adding the more people get vaccinated, the faster we will overcome the virus. that message, the subject of a sweeping new ad campaign, one of the largest public education efforts in u.s. history. >> because getting back to the moments we miss starts with getting informed. >> reporter: it is around 70% effective at preventing illness. the efficacy from moderna and pfizer is roughly 95%. health experts say all three vaccines work. if you are eligible, don't wait. >> we all think that they're in the same ballpark. i would tell any member of my family, get the vaccine that's available right now. >> reporter: in new york city, vaccines got a big boost. after last week's weather delays, the city encouraged people to sign up for a dose. advertising that they had extra supply and were adding overnight appointments and pop-up sites. a shot of ho

meanwhile, the fda could approve use authoriti as soon as tomorrow.ay area counties have reportedly stopped giving vaccine doses to one medical after it gave shots to people who aren't eligible yet. the letter san francisco sent to the company. >>> when are you going to reopen? >> who runs this district? >> upset parents pushing for schools to reopen. the heated board of education meeting in the east bay. >>> good morning. welcome to thursday, february 25th, we'll get to all those stories. first, a check of the weather with meteorologist mike nicco. >> all right, thank you, reggie. i can call the all clear, all wind advisories have expired. the last one was for lake county and it just expired when the clock struck 6:00. so here is a look at our winds, 15 at fairfield. less than 10 to come around the rest of the neighborhoods. there is still a little gusty up in the higher elevations. look at diablo, 60 miles per hour up there. 3800 feet, nobody lives up there. so some of those could work their way down. breezy from time to time. and the temperatures w

we'll hear from the company, the fda, cdc, the public this is a big meeting.uments from the fda likely on february 24th, which will have tons of information about this vaccine that's always a very big day how does that 22-daytime line compare with what we saw with pfizer and moderna it's slightly longer for pfizer they filed on november 20th. their advisory committee meeting was december 10th. for moderna, shorter, filed november 30th. and december 17th was the meeting. why are they scheduling this 22 days after they filed for emergency use authorization? guys, we have seen the fda move with unprecedented speed to clear these vaccines after a positive vote just the day after. this is on a friday for j&j. we'll see if the fda does this over the weekend and we'll see if we see the shots that following monday guys >> hey, meg, before you go, what is the time line on the studies being done for a booster shot on the j&j, whether that would change the efficacy? >> reporter: well, they had an ongoing clinical trial testing two doses. so we don't know exactly when we

the fda authorizing emergency use for johnson & johnson's one-shot vaccine. you're learning new details about the company's rollout plan. >> reporter: that's right, whit. right out of the gate, nearly 3 million doses will be sent to state and local jurisdictions, with 800,000 going to pharmacies. the first shots will likely be administered early this week. whit? >> trevor, thank you. >> now to the covid relief milestone, president biden's massive package clearing the house overnight. president urging the senate to act fast, with unemployment benefits for millions in just two weeks. but that house vote was a narrow victory. all republicans voting no. two democrats voting with them. the battle in the senate now, one of the president's biggest tests yet. here's maryalice parks. >> reporter: president biden before the cameras today marking his first legislative milestone, a big step in getting covid relief to the american people. >> we have no time to waste. if we act now decisively, quickly and boldly, we can finally get ahead of this virus, we can finally get o

david kessler's former head of the fda and is now the chief science officer for the covid-19 response under president biden, the person president biden has put in charge, among other things, of the development and manufacturing and distribution of vaccines and treatments for covid-19. i want to talk about both vaccines and treatments with him tonight. dr. kessler, i'm so grateful that you were able to make the time to be here. thank you so much. >> thank you for having me, rachel. >> so, i have a lot of things that i want to ask you about. i feel like i bottle up questions for you in between the times we're able to talk. but first, i just wanted to ask if you could tell me and tell our viewers why you think the numbers are looking better now over these past few weeks, new case numbers, new hospitalizations, and indeed, in the death numbers? as bad as those numbers still are, the trend lines are in the right direction. is it possible that part of those positive trend lines are because tens of millions of americans have been vaccinated already, or is there any way to tell? >> i don't wa

the fda is going to do a careful review. once this vaccine becomes available it's easy to store, a single shot. it's going make a big difference. >> concern about what could be on the horizon -- dr. fauci and others warned for some time now the uk variant could become the dominant variant right here in the u.s. and within weeks. we know that variant and others already detected in more than 30 states now. are we in a race against time the get the first shot into the arms of americans to slow down the spread and keep these variants from evolving more and get around the vaccine at some point? >> absolutely, we are definitely in a race. i'm confident these vaccines will hold up to the variants. but i'm deeply waired if the variants take off and end up infecting a lot of people we could be -- we have to get the vaccines out to especially high risk people. >> the number of new cases is down, which is encouraging this week. we heard the acting commissioner of the fda say the vaccines will work against these variants, but that now i